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THE ROLE OF IGF-1 IN THE DEVELOPMENT AND PROGRESSION OF 
COLORECTAL CANCER 
ABHINAV SHARMA 
ABSTRACT 
Colorectal Cancer (CRC) is one of the most prevalent cancers among men and 
women in the world. Its presence is increasingly being felt in people who east a western 
diet. A sedentary life, lack of physical activity, and excessive consumption of red meat 
are some of the major risk factors associated with the disease. Furthermore, increasing 
correlations are demonstrating that diabetic and obese patients are at a higher risk of 
developing colorectal cancer. Of increasing interest is the presence of growth factors 
present in these individuals. One such growth factor, which is being crucially studied for 
the purposes of treatment and prevention, is insulin-like growth factor-1 (IGF-1.) IGF-1 
is part of the IGF axis, an endocrine axis, composed of IGF-1 receptor (IGF-1R), 
numerous IGF binding proteins (IGFBPs), and insulin. Many studies have highlighted the 
high levels of IGF-1 in the blood of patients with CRC. However, currently IGF-1 is only 
regarded as a biomarker for CRC. The role that a dysregulated IGF axis plays in the 
development and progression of CRC is largely unknown. This review of the current 
literature has underlined major risk factors of colorectal cancers which are able to exert 
their unwanted effect through their impact on the IGF axis. These factors include obesity, 
diabetes, radiotherapy, and oxidative stress. The understanding of the dysregulation of 
IGF axis’ pathways in colorectal cancer is crucial for the development of new treatment 
options for the disease in the future. 
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In this paper  the known mechanisms through which IGF-1s binding to IGF-1R 
causes unnecessary cellular proliferation in colorectal cancer patients is discussed. IGF-
1R is a dimer with a tyrosine kinase domain on the intracellular side. Ligand binding to 
this receptor causes autophosphrylation and the activation of the Phosphoinositide 3-
kinase/Protein Kinase B/Wnt (PI3K/Akt/Wnt) pathway. The PI3K/Akt/Wnt pathway is 
known to cause cellular proliferation and, in excess, metastasis. The potential for the IGF 
axis to cause metastasis will also be discussed in more direct terms. Levels of IGF-1R 
and IGF-1 are positively correlated with different stages of metastasis. Furthermore, in 
vitro and in vivo studies have demonstrated that IGF-1 has the ability to increase 
lymphatic vessel density. 
 The potential for changes in the treatment of patients with colorectal cancer and 
prevention of the disease in those who are at risk of it is also discussed. Currently the 
main therapies through which the IGF axis is targeted are chemotherapy and 
immunotherapy. However, these therapies can cause a lot of damage to the body as they 
are not specific to the cancer cells. A new theory known as the cancer stem cell theory is 
readily being used to design treatment options for the future. According to this theory, 
cancer stem cells are present in small amounts in everyone and are responsible for the 
relapse of cancer after radiation or chemotherapy. These cells are increasingly being 
targeted for drug design as they provide specificity which would, hypothetically, not 
produce as many side effects. Another mechanism, which provides specificity and is 
gaining popularity in treating CRC, involves the use of microRNAs. microRNAs are 
small RNAs which can bind to mRNAs of major genes and prevent their translation. 
  vi 
miRNAs which suppress the genes of the IGF axis can be administered to the patient to 
specifically address the problem.  Numerous such miRNAs have been discovered and 
their roles were discussed in further detail. 
Lastly,  the ability of some bioactive compounds to perturb the IGF axis in CRC 
is also discussed. These compounds are mainly found in some of the fruits and 
vegetables, and spices like curcumin. Vitamin D is another dietary compound which has 
the potential to prevent CRC in the susceptible population. However the extent to which 
small amounts of these compounds can prevent CRC is largely indeterminate and there is 
a need to conduct studies on the compounds’ dosing regimen. 
The review of the literature on colorectal cancer has discussed some of the latest 
strategies in tackling the disease as well as providing mechanistic insights into IGF axis’ 
dysregulation in CRC.  
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1. INTRODUCTION 
Colorectal Cancer: Definition and epidemiology 
Colorectal cancer (CRC) is a cancer that originates in the colon and/or the rectum. 
In most cases the start of this cancer is associated with the presence of malignant tumors, 
known as polyps, in set areas of the body. As the cancer grows, it can reach nearby lymph 
nodes through which it can metastasize to distant parts of the body like the liver. 
Colorectal cancers can occur due to the abnormal proliferation of the immune cells, 
vascular tissue, interstitial cells of Cajal which help with the pacemaker activity of the 
smooth muscle cells of the colon, hormone producing cells, or mucus secreting glandular 
cells. The cancer resulting from abnormalities in glandular tissue is also known as 
Adenocarcinoma. Adenocarcinoma represents 95% of colorectal cancers and will be the 
focus of this thesis (“What is colorectal cancer?,” n.d.). 
As the third most common cancer amongst men and the second most common 
cancer amongst women, colorectal cancer comprises 10% of all cancer cases worldwide 
(World Cancer Report 2014, 2014). In 2012, 1.2 million new cases, and 694,000 deaths 
were attributed to this cancer (World Cancer Report 2014, 2014). Additionally, 65% of 
these reported cases were found in the developed regions of the world (World Cancer 
Report 2014, 2014). In the USA, an estimated 5% of the population will be diagnosed 
with colorectal cancer in their life (Vargas & Thompson, 2012). Recent advances in 
treatment options have helped in improving patient survival, with a 5-year survival rate of 
65% being observed in 2014 (“Cancer of the Colon and Rectum - SEER Stat Fact 
Sheets,” n.d.). However, diagnosis and treatment in the later stages of cancer continue to 
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be a profound problem. In 2006, 20% of CRC cases were brought to the hospital during 
the final stages of cancer. Of these, only 33% of the patients survived to the 5-year mark 
(Simmonds et al., 2006). In order to combat this problem, cutting-edge developments in 
cancer therapies, research into prevention, identification and diagnosis of CRC in at-risk 
individuals is underway.  
Risk factors  
One of the most basic risk factors associated with CRC is age. In fact, 90% of all 
CRC cases are within individuals that are 50 years or older (Haggar & Boushey, 2009). 
Apart from age, genetics is another non-modifiable variable associated with the incidence 
of CRC. The exact role of genetics remains unclear in several CRC cases and extensive 
research is underway to better understand the role of genetics in the propagation of CRC 
through generations. In spite of this, it has been established that hereditary conditions 
only make up 5-10% of all CRC cases. Of these conditions Lynch Syndrome, Garner 
Syndrome and Familial Adenomatous Polyposis (FAP) are the most common, with 
Lynch Syndrome making up 3% of all CRC cases. Furthermore, patients with Garner 
Syndrome and Familial Adenomatous Polyposis nearly always develop CRC  
(Cunningham et al., 2010; Juhn & Khachemoune, 2010). The impact of genetics is not 
restricted to well-documented hereditary conditions. Individual with 2-3 first degree 
relatives exhibit up to 2-3 fold higher chance of developing CRC. These cases comprise 
20% of all CRC cases, and could hypothetically result from similar environmental and/or 
genetic cues (“Colorectal Cancer Prevention,” n.d., World Cancer Report 2014, 2014; 
Haggar & Boushey, 2009; Potter & Hunter, 2009). 
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In addition to hereditary diseases, several environmental factors are also 
associated with CRC. Habitual activities like excessive alcohol consumption, tobacco 
use, red meat consumption and microbial infections have all been linked to an increase in 
CRC (Baena & Salinas, 2015). Furthermore, individuals already suffering from 
inflammatory bowel disease (IBD; including Chron’s disease and Ulcerative colitis) and 
type II diabetes are more likely to suffer from CRC. Increased inflammation during IBD 
is correlated with an increased risk of CRC. Despite this, IBD patients only comprise 2% 
of all CRC patients. A bigger chunk of cancer results from metabolic problems like type 
II diabetes and obesity. Along with the higher proportions of obesity, the incidence of 
colorectal cancer has also been shown to be higher in developed countries (Vargas & 
Thompson, 2012). However, this does not reduce the risk of citizens of developing 
countries from getting colorectal cancer. Acquisition of a western lifestyle by a person 
from a developing country drastically increases the chances of colorectal cancer. This 
demonstrates the role lifestyle plays in the development of CRC (Potter & Hunter, 2009). 
 
Diet as a preventative measure against CRC 
    Over the years, several preventative measures have been shown to correlate with 
reduced CRC levels. The use of nonsteroidal anti-inflammatory drugs (NSAIDs), like 
Aspirin and Celecoxib, has been shown to reduce the risk of CRC (Cooper et al., 2010; 
Thorat & Cuzick, 2013; World Cancer Report 2014, 2014). Increase in water intake and 
increased physical exercise has also correlated with reduced risk. Similarly, diet has been 
regarded as one of the major contributors in the development of colorectal cancer. 
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Making proper dietary choices is generally considered to be a major preventative measure 
for many forms of cancer. However, the underlying mechanisms for how dietary choices 
influences incidence of cancer is subject of much debate (“Cancer Facts and Statistics | 
American Cancer Society,” n.d., “Cancer Facts and Statistics 2015 | Research | American 
Cancer Society,” n.d.). Epidemiologic studies have revealed that consumption of red 
meat and processed meat can increase the risk of developing colorectal cancer (Santarelli, 
Pierre, & Corpet, 2008). Eating a diet rich in fruits and vegetables is also generally 
advised but its association with a reduction in risk is not as strong and hence not as 
widely accepted (Tárraga López et al., 2014). Similarly, evidence suggesting positive role 
for calcium supplementation and vitamin D uptake also exists (Weingarten et al.,  2008; . 
Ma et al., 2011; Yin et al., 2011). The inconsistency between eating a primarily 
vegetarian diet and the incidence of cancer is widely reported. Riboli and Norat (2003) 
performed a meta-analysis to demonstrate that there are consistently weaker associations 
between vegetarian diet and cancer in prospective studies than in case-control or cohort 
studies. Recall bias is believed to be the major determinant in this disagreement, 
according to their discussion (Riboli & Norat, 2003). Furthermore, a vegetarian diet is 
diverse and, at least from a nutritional point of view, should not be assessed for its role in 
CRC. There are many components to a vegetarian diet including, the variety of fruits, 
vegetables, legumes, fiber components, nuts, and dairy products (Pilis et al., 2014). An 
analysis of each of these components separately would be a more accurate representation 
of the reduction of risk associated with acquiring a vegetarian diet. It would also reveal 
some of the underlying mechanisms of the association.  
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Dietary changes can directly affect the body in numerous ways including changes 
in gut microbiota, metabolism, and endocrine function (Pilis et al., 2014). Indirect 
implications of one’s diet could be interrelated. For example, changes in gut microbiota 
could influence changes in the endocrine function and vice versa. An important system of 
endocrine activity which has been shown to have significant associations with numerous 
cancers is the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis. However 
associations do not denote causation and the exact mechanism through which this axis 
causes cancer is not yet determined (Frago & Chowen, 2005). In this thesis, I’ll be 
examining possible mechanistic links between the GH/IGF-1 axis and CRC. However, it 
is important to understand some well know molecular pathways in CRC before getting 
into further details of the GH/IGF-1 axis. 
Molecular mechanisms regulating CRC progression 
 Like many other cancers, disrupted cell division pathways are primarily 
responsible for the growth of colorectal cancer. Recent studies have shown that CRC can 
result from abnormalities at an epigenetic level. In addition to abnormal methylation 
within tumor suppressing genes, these mutations often include alterations in the levels of 
microRNAs (miR) (Schuebel et al., 2007; Grady et al., 2008; Deng et al., 2011). For 
example, down regulation of miR-137 has been seen in 81% of all colorectal cancer 
(Balaguer et al., 2010). Intensive research is underway to improve the understanding of 
the role of epigenetics in cancer. On the other hand, studies looking at genetic mutations 
have been able to pinpoint the genes important in the development of cancer. One 
specific signalling pathway has been shown to be most prominent in CRC. Mutations in 
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the APC gene within the Wnt signalling pathway have been shown to strongly correlate 
with CRC progression. APC prevents the accumulation of beta-catenin in normal cells. 
The accumulation of beta-catenin, and its subsequent translocation to the nucleus, 
activates pro-oncogenes that assist in abnormal cell growth (Ionov et al., 1993; Abdul 
Khalek et al.,  2010). Other proteins, like AXIN1, AXIN2, NKD1 and beta-catenin itself 
are also capable of preventing the accumulation of beta-catenin (Markowitz & 
Bertagnolli, 2009). However, mutations in APC trump mutations in all of these genes 
during the development of CRC. The abnormal growth resulting from disrupted Wnt 
signalling is often complemented by mutations in cell-killing pathways like TGF-beta 
signalling and p53 signalling pathway. The mutated genes within these pathways (e.g. 
TGF-beta, TP53, SAMD, BAX etc) have reduced tumor suppression capacity 
(Markowitz & Bertagnolli, 2009). In addition to decreased tumor suppressor activity, 
proto-oncogenes (like PTEN, KRAS and RAF) and numerous growth factors (like VEGF 
and EGF) aid in cancer progression by providing the tumor cells with the right milieu for 
proliferation (Vogelstein & Kinzler, 2004).  A generalized picture of the role of various 
growth factors in cancer is shown in figure 1. It should be noted that IGF-1 is one of the 
two growth factors that is important for the early expansion of the mutated cell. Despite 
being generalized as an important mediator of cancer growth, the exact role of IGF-1 in 
CRC remains to be deciphered. 
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Figure 1: Role of growth factors in cancer. 
This figure outlines the generalized process of a cell’s metastasis in cancer and the 
various cytokines and growth factors involved. IGF-1, as shown, is particularly 
responsible for the early clonal expansion of the cancerous cells(Witsch, Sela, & Yarden, 
2010).  
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GH/IGF-1 axis in metabolism and cancer 
The GH/IGF-1 axis is comprised of GH, IGF-1, IGF-II, Insulin, Insulin Receptors 
(IRs like IRA and IRB), IGF-1 receptors (IGF-1Rs), Growth Hormone Receptor (GHR), 
six high affinity IGF-1 binding proteins (IGFBP 1-6), and IGFBP regulatory proteins. 
Together these components help regulate metabolism, somatic growth, and ageing events 
(Werner & Bruchim, 2012).  
IGF-1 and IGF-2 are peptide hormones that share a 40-80% homology with 
insulin. Insulin is a monomer consisting of two chains, alpha and beta, linked together by 
two disulfide bridges. IGF-1 and 2 are single chain polypeptides with an alpha and a beta 
domain. These domains are similar to the two insulin chains. IGF-1 receptors (IGFRs) 
and insulin receptors (IRs) are also similar to one another. These receptors are 
hetrotetrameric proteins. They have two extracellular alpha subunits and two 
transmembrane beta subunits. The beta subunits contain a tyrosine kinase domain which 
can autophosphorylate upon ligand-receptor interaction. The homology between the two 
receptors gives rise to some crosstalk between insulin and IGF-1, as shown in the figure 
below (Singh et al., 2014). The impact of insulin based IGF-1R related signalling on the 
development of CRC remains to be seen. However, it is tempting to speculate that 
increased insulin levels in type II diabetics could be the cause of IGF-1 signalling based 
CRC progression. Prior to jumping to such speculations, it is important to first understand 
the role of IGF-1 in normal and cancer physiology. 
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Figure 2: Crosstalk between IGF-1 and Insulin with each others’ receptors (Singh et al., 
2014). 
This figure outlines the interactions of IGF-1 and insulin with each others’ receptors. 
IGF-1 has the potential to bind and activate IGF-1R as well as IRB:IGF-1R and 
IRA:IGF-1R (not shown). Although, IGF-1’s activation of hetrodimeric receptors are not 
very strong. 
 
While numerous studies have correlated overproduction of IGF-1 with cancer, the 
regulation of the expression of IGF-1 has not yet been properly defined. As far as it is 
known, IGF-1 can be secreted from a range of different cell types (ranging from 
hepatocytes to tumor cells) (Baxter, 2014). Liver is the main site of IGF-1 production. 
Liver IGF-1 circulates throughout the body as an endocrine factor, whereas IGF-1 
produced in other parts of the body serves more of an autocrine/paracrine role (Donovan 
& Kummar, 2008).  
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The secretion of IGF-1 is primarily under the control of Growth Hormone (GH). 
GH is a peptide secreted by cells of the anterior pituitary gland in response to the gland’s 
activation by GHRH (Growth hormone releasing hormone), which itself is released from 
the hypothalamus. GH exerts its effects through GH receptors (GHRs) on target cells. 
GHR is a single transmembrane protein which, unlike IGF-1Rs and IRs, lacks an intrinsic 
tyrosine kinase activity. Instead, upon ligand interaction, it recruits proteins from the JAK 
family which contain tyrosine kinase activity necessary for downstream cascade and 
cellular proliferation (Frago & Chowen, 2005). Growth hormone also mediates its action, 
indirectly, via the induction of IGF-1 in target cells. 
IGF-1 levels can also be regulated by IGF binding proteins (IGFBPs). IGFBPs 
and their proteases regulate the balance of free IGF-1 in the blood and its subsequent 
interaction with IGF-1R. This feature of IGF-1 regulation distinguishes it from insulin. A 
recent in nature reviews cancer by Robert C. Baxter (2014) summarized most of the 
current knowledge regarding the role of IGFBPs in cancer. 
The nature of IGFBPs is complex and dependent on the type of IGFBP in 
discussion and its context within the body’s physiology. There are 6 types of IGFBPs, 
IGFBP1-6. These six proteins each have three domains of which the amino and carboxy 
terminal regions are highly conserved and are made of a disulfide constrained structure. 
The third domain is a linker domain and is the main source of divergence between the 
proteins. The functions of IGFBPs can be classified as IGF-1 dependent and IGF-1 
independent.  This difference is crucial as it helps to determine the opposing roles of 
IGFBPs in cancer regulation. IGF-1 independent roles are generally intracellular and help 
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stimulate cell growth and survival. But the implications of these findings are beyond the 
scope of this paper. 
IGF-1 dependent roles primarily involve extracellular circulating IGFBPs. Here 
they are able to bind to IGF-1 to increase its stability and help with its transportation to 
appropriate compartments of the body. Of the six proteins, IGFBP3 is the most 
extensively studied. This protein along with, acid labile subunit (ALS) binds and 
stabilizes IGF-1. Other IGFBPs form binary complexes with IGF-1 and are not as 
prevalent, as seen in figure 3 (Baxter, 2014). 
 
 
Figure 3: Binding of IGF-1 to components in circulation (Baxter, 2014) 
This figure is a schematic of the various forms of IGF-1 found in the blood. IGF-1 in a 
complex with IGFBP3 and ALS forms a ternary complex has the longest half life 
whereas free IGF-1 has the shortest half-life. 
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In addition to providing stability, IGFBPs inhibit IGF-1 signalling by preventing 
the binding of IGF-1 to IGF-1R, which in turn prevents growth and differentiation of 
cells. Furthermore, IGFBP1 and 2 have been shown to be related to an individual’s diet 
and energy balance. They are upregulated during starvation and downregulated in the 
presence of insulin. Consequently, these proteins are under expressed in obese and 
diabetic patients. The low levels of IGFBPs causes an increase in free IGF-1 and hence 
an increase in the risk of cancer (Baxter, 2014).  
In the following thesis the role of IGF-1 in the prevention of colorectal cancer will 
be discussed. 
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2. SPECIFIC AIMS 
A lot of studies have correlated the levels of IGF-1 with the incidence of 
colorectal cancer. However, levels of IGF-1 in blood are only considered as biomarkers 
and not as part of causation of the CRC. There is a need in science to understand and 
evaluate the contribution of IGF-1 to the development and progression of CRC. In this 
study: 
 
1. The molecular mechanisms for the upregulation of free IGF-1 in the development 
of CRC will be determined. 
3. The pathways through which high levels of IGF-1 contribute to cellular 
proliferation and metastasis in colorectal cancer will be understood. 
4. Current endogenous mechanisms which may be responsible for the inhibition of 
the IGF axis in CRC and can provide us with future treatment options will be 
discussed. 
4. The role of bioactive compounds and their ability to perturb the IGF axis in 
colorectal cancer will be briefly discussed. 
 
Through the  assessment of recent studies mechanistic insight into IGF-1 
dependent increase in the incidence of CRC will be determined. Furthermore the future of 
the disease in terms of developing treatment options will be discussed. 
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3. PUBLISHED STUDIES  
3.1 There is a higher ratio of Insulin Receptor A: Insulin Receptor B (IR-A:IR-B) in 
colorectal cancer patients. 
 
Table 1: Insulin receptor biomarkers in CRC patients. Levels of mRNA of IGF1R, IR, and 
IRA:IRB in human populations are analyzed and grouped according to BMI ranges of Normal 
and Obese or Insulin levels of low or high. Significance p values are listed in the right column 
(Santoro et al., 2014). 
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IGF-1 has been shown to be able to cross talk with the insulin receptors (IRs). IR-A is 
responsible for proliferation of cells. IR-B is primarily responsible for metabolic 
functions. A high ratio of IR-A:IR-B has been indicated in some colorectal cancers. 
Normal colorectal tissue of patients with CRC was collected and screened for IR-A and 
IR-B levels. An increase in IR-A:IR-B ratio was seen in patients with CRC who also 
showed high levels of insulin (p<0.05). Patients classified otherwise – low insulin, 
normal BMI, obese BMI, all together – did not show any significance in IR-A:IR-B 
(Santoro et al., 2014). 
3.2 IGF-1 induces phosphorylation of the Akt pathway in CRC cell lines and isomer 
of Conjugated Linoleic acid (CLA) reduced this phosphorylation in CRC cell lines. 
 
 
Figure 4: IGF-1 induced Akt phosphorylation is inhibited by CLA. Immuno-blot of p-Akt 
and Akt in HCT-116 (top) and HT-29 (bottom) CRC cell lines with or without exposure to CLA 
isomer inhibitor and subsequent treatment with or without IGF-1 (Kim et al., 2015). 
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Delineating the downstream mechanism activated upon IGF-1 exposure to CRC cells is 
vital in obtaining possible inhibitors towards the IGF-1 effect. Phosphorylation of Akt 
was seen upon IGF-1administration to both CRC cell lines (Figure 4). An isomer of the 
commonly found, Cis 9, trans 11-Conjugated Linoleic Acid (c9, t11-CLA), an ingredient 
found in meat and dairy products, was shown to reduce IGF-1 mediated Akt 
phosphorylation on these cell lines (Figure 4). The isomer, t10, c12-CLA, is uncommon 
in regular products but is present in up to 35-45% of synthetically prepared CLA (Kim et 
al., 2015). 
3.3 High fat diet causes high IGF-1 levels and elevated levels of cell proliferation 
markers in mice. 
 
 
Figure 5: High fat diet leads to elevated CRC biomarkers. Serum IGF-1 levels in CRC model 
mice on a normal diet (ND) or a high fat diet (HFD) for 16 weeks are presented in D). Percent of 
Ki-67 stained cells in mice on a ND or HFD are presented in E) (Q.-C. Zhu, 2014). 
 
To understand the potential co-relation between western diets and cancer onset rats were 
either fed a high fat diet (45% fat, 35% carbs, 20% proteins) or a normal diet (13.5% fat, 
58% carbs, 28.5% proteins). All the while they were injected with 1,2 DMH 
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(dimethylhydrazine), an inducer of CRC. They were euthanized at 16 weeks. A high fat 
diet also showed increased serum IGF-1 levels after 16 weeks (Figure 5D). Since IFG-1 
has been shown to induce Akt phosphorylation, a pathway which can aid in the 
proliferative capacity of cancer cells, cell proliferation was analyzed in CRC model mice 
with a HFD. Staining was performed using Ki-67, a cell proliferation marker used as a 
precursor in determining cancer onset. A high fat diet was shown to have more Ki-67 
positive cells as compared to a normal diet thereby demonstrating higher proliferation 
(Figure 5E) (Q.-C. Zhu, 2014).  
3.4 miRNA-29b can downregulate expression of IGF-1 and IGF-1 induced 
downstream pathways in CRC cell lines in vitro. 
 
Figure 6: miR-29b downregulated IGF-1 pathway. PLV-miR29b indicates the presence of a 
plasmid with miR29b. All CRC cell lines display reduction of IGF-1 and decreased 
phosphorylation of PI3K and Akt when transfected with PLV-miR29b (Yuan et al., 2015). 
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Figure 7: miR-29b downregulated IGF-1 mediated proliferative pathways. Re-induction of 
IGF-1 into cells with miR29b plasmid promotes proliferation ability D) and increased 
phophorylation of Akt E) (Yuan et al., 2015).  
 
 IGF-1 expression in CRC cell lines can cause the progression of the CRC. 
miRNA29b, an endogenously found miRNA, binds to the 3’UTR of IGF-1 mRNA to 
inhibit its translation. PLV (lentivector) was transfected with miRNA29b, inserted into 
cancer cell lines and their expression of IGF-1 was studied at the protein level in vitro 
(Figure 7C). IGF-1 expression was downregulated in all four cell lines with miRNA29b. 
Activation of downstream pathways associated with the IGF-1 axis was also studied in 
these cell lines after vector transfection. There was a lack of PI3K and Akt 
phosphorylation in cancer cells transfected with miRNA29b vector (Figure 8D). 
Administration of exogenous IGF-1 in cell lines transfected with PLV-miR29b rescued 
the proliferative capacity of these cells (Figure 7D). Exogenously administered IGF-1 
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also induced the phosphorylation of PI3K and Akt in PLV-miR29b cells (Figure 7E) 
(Yuan et al., 2015). 
 
3.5 Interferons (IFNs) induce nuclear factor IRF1 expression, which can upregulate 
miRNA-29b expression. 
                    
Figure 8: IFNs upregulated miR-29b expression. C) There is a time dependent inverse 
correlation between IGF-1 and IRF1 in cancer cells which have IFN-y administered upon them. 
D) Transfection with IRF-1 vector in SW420 and SW620 cells promote miR-29b production 
(Yuan et al., 2015). 
 
 Understanding how miR-29b is being regulated can lead to further understanding 
of how IGF-1 is being regulated in patients. Previously miR-29b has been shown to be 
upregulated and necessary in efficient functioning of innate immunity (F. Ma et al., 
2011). miRNA-29b expression was studied after IFNs, important cytokines of the innate 
immune system, were exogenously administered on CRC cell lines. Expression of IRF-1, 
a transcription factor regulating miRNA-29b expression, was seen to be upregulated in a 
time dependent manner at the protein level in SW480 and SW620 cell lines when IFN-y 
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was administered (Figure 8C). A decrease in IGF-1 levels was seen in the same cell lines, 
also in a time dependent manner (Figure 8C). Further, IRF-1 vector were administered in 
SW480 cells and miRNA-29b expression was studied. IRF-1 caused an upregulation of 
miRNA-29b in both CRC cell lines (Figure 8D) (Yuan et al., 2015). 
 
3.6 IGF-1 binds to IGF binding protein-2 (IGFBP-2) over IGF binding protein-3 
(IGFBP-3) in CRC patients. 
 
Figure 9: IGF-1 prefers binding to IGFBP-2 over IGFBP-3 in CRC patients. Ligand blotting 
assay for healthy (H) and CRC individuals (T) for IGFBPs 2 and 3. Serum from H and T 
individuals was blotted with radioactive IGF-1 and imaged (Nedić et al., 2013).  
 
 IGF-1 can also be regulated in the blood stream and the oxidative state of the 
tissues is one of the ways this occurs. Oxidation is one of the early hallmarks of cancer 
and cancer initiation and progression has been related to oxidation in many cancers, 
including CRC. Oxidation of IGFBPs increases the binding affinity of IGF-1 to IGFBP-2 
and decreases the affinity towards IGFBP3. IGFBP2-IGF-1 can cross endothelial barrier 
and help with tumor growth. IGFBP-3 binding to IGF-1 has suppressive effects on IGF-1 
properties. Tissues blotted with radioactive IGF-1 and imaged are shown in Figure 16. In 
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healthy patients IGFBP-3 was found to bind to IGF-1, whereas in patients with CRC 
patients IGF-1 is seen to bind to IGFBP-2 (Nedić et al., 2013). 
 
3.7 Radiation induces upregulation of IGF-1 and downregulation of IGFBP3 in in 
vivo models of CRC. 
 
Figure 10: Radiation favored upregulation of CRC biomarkers. Serum of mice exposed to 2 
Gy gamma radiation for 2 months (A, B and C) and 12 months (D, E and F) were analyzed for 
IGF-1 and IGFBP-3 production (Suman et al., 2015). 
 
As with oxidative stress, other external sources can impact the progression and onset of 
CRC. Radiation is one such external source which is commonly used as a therapy in 
fighting CRC. 2 Grays (Gy), a common dose in fractionated radiotherapy, was 
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administered onto mice with CRC. Diagnostic markers of CRC – IGF-1, IGF-1R and 
IGFBP-3 – were then analyzed. Mice exposed to radiation showed higher levels of serum 
IGF-1 and lower levels of IGFBP-3 significantly after 2 months and 12 months (Figure 
10). This information sheds light into the potential consequences of treating CRC with 
radiotherapy (Suman et al., 2015). 
 
3.8 IGF-1 can promote the metastasis of CRC. 
 
Figure 11: IGF-1 promoted metastatic characteristic of CRC. LoVo cells were injected into 
nude mice and allowed to grow under control (A) and IGF-1 treatment (B). LVD (lymph vessel 
density) of the IGF-1 group was significantly higher than the control group (Li, 2013). (10.7 ± 3.3 
vs 6.4 ± 2.9, P < 0.05) 
 
To evaluate other physiological properties of only IGF-1 that could contribute to cancer 
progression, the role of IGF-1 in CRC and its potential in metastasis was studied. LoVo 
(human colon cancer cell line) was used to perform in vivo analysis. Histological staining 
of tumor sections to measure LVD was used as a means to determine the metastatic 
potential of the cancer. Quantification of vessel staining showed a significant 
upregulation of vessels in implanted CRC tumors (Li, 2013). 
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3.9 Higher IGF-1R levels but not IGF-1 levels are co-related with advancement of 
CRC. 
 
Figure 12: IGF-1R levels are co-related with metastasis stage of CRC. IGF-1 and IGF-1R 
mRNA levels were determined in CRC patients and grouped according to the stage of the cancer. 
Stages of cancer: Dukes stage A – Confined to Mucosa, B – Growth through the muscle layer, C 
– Lymph node metastasis present, D – Widespread metastasis (Liu et al., 2014). 
 
IGF-1 and IGF-1R expression levels were studied with regards to different stages of 
cancer progression, to look for a co-relation between metastasis and these biomarkers in 
human patients. RT-PCR was used to determine relative mRNA levels of both IGF-1 and 
IGF-1R. IGF-1R levels were seen to be upregulated in Dukes C+D, the later more 
metastatic stages of cancer (Figure 12B). However, IGF-1 levels did not change with 
regards to the stage of cancer (Figure 12A) (Liu et al., 2014). 
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3.10 miR-143 and miR-145 effectively downregulate the expression of IGFR1 in 
vitro. 
 
Figure 13: miR-143 and miR-145 downregulated IGF-1R expression. CRC cell lines were 
treated with miR-143/145 and total mRNA levels were measured through qPCR in A). Upon their 
induction, the IGF-1R protein levels were measured via western blots in B) and quantified using 
densitometry C). mRNA levels of IGF-1R for the different treatments were measured via qPCR 
and expressed in D) (Su et al., 2014). 
 
As observed from previous studies IFG-1R can be an important biomarker in CRC and 
can induce cell proliferative effects leading to cancer metastasis and progression. It is 
also the main receptor through which IGF-1, another vital biomarker in CRC, 
communicates. Therefore the regulation of IGF-1R is important to understand. The 
effects of two endogenously produced miRNAs (143 and 145) were studied. miRNA-143 
and miRNA-145 were exogenously administered in Caco-2 cancer cell lines in vitro. 
Both the miRNAs were found to be stable in cell, as upon their administration an increase 
in their miRNAs was seen (Figure 13A). Administration of exogenous miR-143 and miR-
145 caused a significant decrease in the production of IGF-1R on the protein level, as 
seen by western blots and subsequently quantified relative to total GAPDH in the cell 
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(Figure 13B and 13C). No effect on the mRNA levels of IGF-1R were seen (Figure 13D) 
(Su et al., 2014). 
 
3.11 miRNA-143 suppresses properties of tumor which could lead to metastasis. 
           
Figure 14: miR-143 suppressed metastatic potential of CRC. Mice models of CRC were 
harvested and their tissue analyzed for endogenous expression of miR-143 when metastasis was 
present or absent in D). Angiogenesis quantification was conducted in tumors of these mice in A) 
(Qian et al., 2013).  
 
As miR-143 has been shown to downregulate IGF-1R expression in CRC cell line, in this 
study the role of miR-143 in reducing metastasis was investigated. Mice with CRC were 
studied for metastasis and were separated in two groups – those with lymph node 
metastasis and those without lymph node metastasis. Normal and cancer tissue was then 
isolated and analyzed for miR-143 expression. miR-143 levels was significantly lower in 
tumors of mice that display metastasis than in mice that were negative for lymph node 
metastasis (Figure 14D). Another measure for evaluating metastatic potential of a tumor 
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is measuring angiogenesis. Figure 15A, shows the relative angiogenesis in the tumor that 
expressed miR-143 versus a tumor that did not express miR-143; there is a significant 
decrease in angiogenesis in tumors that express miR-143, when quantified (Qian et al., 
2013). 
 
3.12 PC (proprotein convertase), Furin, can be inhibited by curcumin, preventing 
the conversion of pro-IGF-1R to IGF-1R. 
                                
 
Figure 15: Curcumin inhibited active IGF-1R expression. Effects of Curcumin on the IGF-1R 
production pathway were analyzed via western blots in A) and effects on PC activity in CRC cell 
lines was analyzed in B) (Zhu et al., 2013). 
 
IGF-1R can also be regulated at the pro-protein form. Pro-IGF-1R needs to be converted 
to IGF-1R by PCs, furin, to be active. And as the anti-cancerous effects of the curcumin 
are being investigated as being a PC inhibitor, curcumin was studied in a CRC in vitro 
model. Curcumin was administered on SW480 cell lines after pre-incubation with IGF-1. 
Addition of 10uM and 20uM of curcumin increased the pro-IGF-1R levels in CRC cell 
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line (Figure 15A). This is inversely co-related with the levels of α-chain of the receptor: 
curcumin administration lowered α-chain levels (Figure 15A). These concentrations of 
curcumin also abolished the intracellular phosphorylation of Akt caused by IGF-1 
administration (Figure 15A). As a potential mechanism behind how curcumin could 
cause pro-IGF-1R aggregation curcumin effects on proprotein convertase (furin in this 
case) were examined. Curcumin decreased the mature form of furin from being formed in 
a dose dependent manner (Figure 15 B). Further in the paper the activity of furin has been 
shown to be reduced after administration of curcumin in a dose dependant manner (data 
not shown). This could suggest a potential mechanism behind the therapeutic effects of 
curcumin (. Zhu et al., 2013). 
 
3.13 Higher levels of IGF-1 and IGF-1R are present in patients with Type-2 
Diabetes (TY2D) and colorectal adenocarcinoma (CA) than with just CA. 
 
Figure 16: CRC patients with TY2D exhibited higher levels of CRC biomarkers. RT-PCR 
determined mRNA levels of IGF-1 and IGF-1R were analyzed in patients’ tissues (cancerous and 
adjacent to cancerous) with CRC (referred to as CA above) (Liu et al., 2014).   
Other aspects of diet can aid in the prevention of CRC. High fat diet was previously 
shown to enhance cancer progression (3.3). High insulin levels have also been seen to 
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have characteristics that could create high IRA:IRB levels, a potentially detrimental 
combination in CRC patients (3.1). Since high insulin is often associated with TY2D the 
expression of prognostic colorectal cancer markers were studied in patients with or 
without TY2D with CRC. Samples from adjacent non-cancerous tissue and cancerous 
tissue was collected and grouped according to whether the patient had TY2D or not. It 
was noted that patients with TY2D had a higher expression of both IGF-1 and IGF-1R 
(Figure 16A and B). Levels of IGF-1 and IGF-1R were higher in the cancerous tissue 
(CT) of all patients when compared to adjacent non-cancerous (ANCT) tissue (Figure 16 
A and B) (Liu et al., 2014). 
3.14 Role of diet induced obesity (DIO) and calorie restriction (CR) on IGF-1 and 
CRC. 
 
Figure 17: DIO mice models of CRC displayed higher levels of CRC biomarkers. Levels of 
IGF-1 and IGFBP-3 were measured in the serum of mice models of CRC with a calorie restricted 
diet or a high fat diet (Olivo-Marston et al., 2014). 
 
CRC incidences are highest in the western countries with high rates of overweight and 
obesity. Studying the effects of diet on cancer progression is necessary in understanding 
the risks leading to CRC and preventative measures that can be taken. Mice CRC models 
were put on three separate diets for 5 weeks: calorie restricted (CR) diet, control diet and 
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a diet inducing obesity (DIO). Mice were euthanized and markers for CRC were 
evaluated. There were significantly higher levels of IGF-1 in serum of mice on DIO with 
respect to mice on CR diet (Figure 17A). DIO mice also had significantly lower IGFBP-3 
levels than mice on a CR diet (Figure 17B) (Olivo-Marston et al., 2014). 
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4. DISCUSSION 
 Preventative measures to counter cancer through changes inlifestyle seem like the 
most ideal way to counter the disease in the future. Colorectal cancer is a prime example 
of this strategy since changes in physical activity and dietary habits have been associated 
with a reduced risk of acquiring the disease. Furthermore, changes in physical activity 
have also shown to reduce the progression of the disease in people already diagnosed 
with CRC (Van Blarigan & Meyerhardt, 2015). 
Although numerous studies have been published associating CRC with various dietary 
and biological factors, little is understood with regards to their underlying mechanisms. 
During the process of this research, it was noted that many of these factors, whether 
external or internal, are linked to IGF-1. In this discussion an in-depth examination of the 
mechanisms involving IGF-1 in Colorectal Cancer will be determined. 
Many studies have correlated the high levels of IGF-1 with incidence of CRC 
(Brahmkhatri et al., 2015). But few have evaluated the external factors which are able to 
adversely influence the levels of IGF-1. In the results it was discovered that generally 
known risk factors for numerous cancers like oxidation, radiation, and a high fat diet have 
a direct impact on the levels of IGF-1 in the blood. TY2D patients with CRC have higher 
mRNA levels of both IGF-1 and IGF-1R than other CRC patients without TY2D. In 
addition, as shown in figure 19, the change in this expression will cause patients with 
TY2D to have a significantly shorter lifespan (Liu et al., 2014). 
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Figure 18: Relapse-free and overall survival rates of individuals with CRC but differing 
levels of IGF-1 and IGF-1R.(Liu et al., 2014) 
The survival of CRC patients with higher levels of IGF-1 or IGF-1 mRNA is lower than 
those without high levels of these mRNAs. This is the case for patients who did not have 
a relapse of the cancer and for the entire patient population which was sampled. 
 
Rats on a high fat diet have higher levels of IGF-1 mRNA, lower levels of IGFBP3, and a 
higher likelihood of developing CRC (Olivo-Marston et al., 2014;  Zhu, 2014). Ionizing 
radiation has a similar effect in the sense that it has been shown to increase the ratio of 
IGF-1:IGFBP3 in the serum of rats over a period of time (Suman et al., 2015). Oxidative 
processes also impact the IGF axis by decreasing the presence of IGFBP3 and increasing 
the presence of IGFBP2 (Nedić et al., 2013). When not oxidized, IGFBP2 exists as a 
dimer with a protein called alpha2M. But upon oxidation, this complex dissociates and is 
more likely to bind to IGF-1 (Šunderić et al., 2014). IGFBP2/IGF-1 complex is much 
smaller than the ternary complex that IGFBP3 forms with IGF-1. Due to its size, the 
IGFBP2/IGF-1 complex has the ability to cross the endothelial barrier. The level of free 
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IGF-1 is very low in the interstitial space and the IGFBP2/IGF-1 complex would have to 
dissociate in order for IGF-1 to maintain equilibrium. This would then expose a higher 
level of IGF-1 to cells in the interstitial space (Nedić et al., 2013). Hence, the size and 
nature of interaction of IGFBP2 with IGF-1 makes it an effective shuttle of IGF-1 
through the endothelial barrier. This role of IGFBP2 is contrary to the conventional belief 
that all IGFBPs help to reduce the IGF-1/IGF-1R interaction. 
Once free IGF-1 is able to bind to IGF-1R, it initiates a downstream pathway leading to 
cell proliferation. IGF-1R activation eventually activates intracellular protein PI3K which 
phosphorylates Akt to make pAkt. pAkt is important because it can potentiate the Wnt 
signaling pathway necessary for proliferation. This is one of the pathways known to be 
dysregulated in CRC cells (Kim et al., 2015). 
It is important to note that even though there are dysfunctional processes occurring in the 
tumor cells of a Colorectal Cancer patient, there are also some that occur in the adjacent, 
seemingly normal tissue. As seen in the results above, this normal tissue has a higher 
ratio of IRA:IRB in people with high levels of insulin. IRA is responsible for the 
proliferative effects of insulin while IRB for the metabolic ones (Santoro et al., 2014). 
Insulin receptors are also a part of the IGF axis as they can be activated by IGF-1, 
although not as strongly as insulin. This finding implies that the high levels of IGF-1 
present in CRC patients may also be able to interact with an adversely affect normal 
tissue (Brahmkhatri et al., 2015). These interactions could potentially be responsible for 
the growth of the tumor and/or metastasis. Hence IGF-1 may be helping in the 
progression of the disease.  
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The metastatic potential of IGF-1 in CRC has only recently been highlighted in literature. 
In vivo analysis has shown that IGF-1 has the ability to increase the density of lymphatic 
vessels around a tumor, implying its ability to induce lymphatic metastasis (Li, 2013). 
IGF-1 mRNA is also found in higher levels in stages C and D of Dukes Classification of 
CRC. Stage C entails the involvement of lymph nodes and stage D is the last stage 
defining widespread metastasis (Liu et al., 2014). Furthermore, IGFBP3 is associated 
with a slower progression of metastatic CRC and IGF-1 has been shown to be involved in 
peritoneal metastasis. Peritoneal metastasis accounts for up to 25% of distant metastasis 
in CRC patients. Around 50% of CRC patients develop metastasis, most of which are to 
the liver via the portal vein system. As shown in the figure below, the levels of IGF-1 are 
markedly higher at the site of peritoneal tumor suggesting that it may be responsible for 
the growth of the tumor at this distant site. The figure below also specifies the knowledge 
of known molecules which are upregulated in the process of peritoneal metastasis. The 
identification of  molecules is helpful in providing us with targets for future therapy in 
CRC (de Cuba et al., 2012). 
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Figure 19: Proposed molecules involved in the steps of a primary tumor’s metastasis to the 
peritoneum (de Cuba et al., 2012). 
This figure shows the presence of endogenous molecules in different steps leading to 
peritoneal metastasis in CRC patients. As shown, IGF-1 is primarily responsible for the 
proliferation of cancerous cells at the site of the metastasis. 
 
Recently published studies have tried to identify numerous molecules and pathway which 
can play an inhibitory role in the regulation of IGF-1 in CRC. These provide endogenous 
targets useful for the treatment of CRC. 
A major development in this field is investigating the role of microRNAs in the IGF axis. 
miRNAs are small RNAs which can bind their compliment mRNA and prevent 
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translation or enhance degradation of the gene. In the effort to suppress a protein which is 
responsible for a cancer or disease, miRNAs which naturally suppress the molecule are 
first identified. An assumption could be made that these miRNAs are either 
downregulated in the cancerous state or should be upregulated to prevent overexpression 
of the oncogene. In an effort to increase the presence of miRNAs in vivo, a few delivery 
systems have been devised. These include the use of liposomes and viral vectors. 
However, sometimes natural miRNAs prevent the translation of a tumor suppressor. If 
there is a need for the reduction of miRNA, synthetic inhibitors could also be used 
(Fortunato et al., 2014). 
The results have underlined a few miRNAs which have the ability to perturb the IGF axis 
in CRC. miR143 and miR145 have been shown to bind to the 5’ untranslated region of 
the IGF-1R mRNA and prevent translation. In vitro administration of these miRNAs 
reduced the proliferation of the CRC cell line (Su et al., 2014). Along with IGF-1R 
suppression, miRNA 143 has also been shown to inhibit angiogenesis and lower levels of 
miRNA 143 are present in patients with lymph node metastasis (Qian et al., 2013). These 
finding are consistent with the earlier discussion of IGF-1Rs presence in Dukes stage C 
and D of CRC. Hence miRNA143 may be part of the mechanism which prevents the 
IGF-1R mediated metastasis in anti-cancerous tissue. Another microRNA, miRNA223, is 
also able to inhibit the expression of IGF-1R. As shown in the figure below, 
miRNA223’s levels are increased, while those of IGF-1R are decreased, as a mouse, 
presumably successfully, fights CRC. But its levels are significantly decreased in vivo, as 
are those of miRNA133a, in inflammation induced CRC. In addition, miRNA143, 145, 
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133a, and 223 dysregulation increase cellular proliferation through the activation 
PI3K/Akt pathway. PI3K/Akt pathway, as mentioned earlier, is one of the main pathways 
used by IGF-1 to cause proliferation in CRC. Hence, it could be inferred that the 
mechanism of action of this group of miRNAs is localized to the IGF-1/PI3K/Akt 
pathway. Such a finding could have numerous pharmacological benefits in the future 
because it delineates the specificity of the miRNAs. Another point of interest is that it is 
hypothesized that these miRNAs are especially suppressed in inflammation mediated 
CRC, which adds another external factor to the list of those able to induce CRC through 
the IGF axis (Josse et al., 2014). 
 
Figure 20: Levels of IGF-1R mRNA and miRNA 223 in inflammation induced CRC over 
the period of 65 days (Josse et al., 2014). 
As shown in the figure, the levels of miR-223 are inversely correlated with those of IGF-
1R mRNA. This indicates the role of miR-223 in the breakdown or suppression of IGF-
1R mRNA. 
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Downregulation of miRNA497 and miRNA29b are also responsible for the disruption of 
the IGF axis in CRC. miRNA497 binds to and prevents translation of IGF-1R mRNA, 
while also inhibiting the potential of a CRC cell to invade as shown in the figure below 
(Guo et al., 2013). 
 
Figure 21: The ability of CRC cells to invade, on an invasion assay kit membrane, in the 
presence of IGF1R and/or miRNA 497 (Guo et al., 2013). 
This figure shows that, under the presence of miR-497 a CRC cell loses its ability to 
invade surrounding locations as shown by the injection of miR-497 and IGF-1R cDNA in 
the cell line. This implies that miR-497 plays a role in IGF-1R mediated metastasis. 
 
miRNA29b binds to the 3’ untranslated region of IGF-1s mRNA and can inhibit 
metastasis of CRC. miRNA29b is regulated by interferon gamma, a soluble cytokine 
released by the immune cells of one’s body in response to a viral infection. When 
interacting with a cancerous cell these interferons can bind to the cell surface and initiate 
a cascade pathway leading to the activation of IRF1. IRF1 is a transcriptional regulator 
and in this case increases the expression of miRNA29b. This ability of the immune 
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system to counter cancerous cells is appreciated in both treatment designs of 
immunotherapy and as potential preventative measures of CRC (Yuan et al., 2015). 
However, treatment of a cancer patient with interferons has the potential to offset 
immune homeostasis, and cause unnecessary interaction with other types of cells, which 
is not always desirable, especially in the susceptible population (Lin & Young, 2014). To 
evade this problem it is important to delineate the pathway through which interferon 
gamma regulates CRC. Hence, the discovery of miRNA29b is important as it provides 
the potential for a localized therapy with little side effects. 
 
Figure 22: Schematic introducing the proposed role of interferons in preventing metastasis 
(Yuan et al., 2015). 
This schematic shows the interferon pathway responsible for apoptosis of cells. A 
cytokine, IFN-gamma, binds the cell surface and activates STAT1. STAT1 helps in the 
activation of IRF1, a transcriptional regulator of miR-29b. The translocation of IRF1 to 
the nucleus increases expression of miR-29b, which binds to and inhibits the expression 
of IGF-1. This prevents metastasis and activates the apoptosis pathway. 
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miRNAs provide a unique scheme of targeting CRC in the sense that they are able to stop 
the dysregulated pathway at the mRNA level without altering the genetic code. However, 
the development of miRNA delivery systems are still in their preliminary stages (Chen et 
al., 2015). Recent developments in the field of cancer therapeutics have prompted other 
approaches to the treatment of CRC. One such approach targets cancer stem cells. Cancer 
stem cells are part of a theory which identifies the presence of these cells, in small 
amount, in all human beings. The survival of these cells from chemotherapy and 
radiotherapy is responsible for the relapse of cancer. The IGF axis is increasingly been 
shown to help with the proliferation of these cells. Direct inhibition of IGF-1R in these 
cells has shown some promise in the treatment of CRC. But the downregulation of IGF-
1R may be inhibiting CRC progression through more than just the PI3K/Akt pathway. 
IGF-1R downregulation in cancer stem cells also reduces the levels of IDI-1. IDI-1 is an 
essential enzyme in the formation of farnesyl pyrophosphate from acetyl-CoA as shown 
in the figure below. This pathway, referred to as the mevalonate-isoprenoid biosynthesis 
pathway, is the same one targeted by Statins in the treatment of cardiovascular diseases. 
Farnesyl pyrophosphate is responsible for numerous biological processes including 
cholesterol synthesis, protein synthesis, proper electron transfer chain functioning, and 
production of prenyalted proteins. The inhibition of these processes can eventually lead 
to cell apoptosis. This provides us with another mechanism of IGF-1Rs role in CRC 
(Sharon et al., 2015). 
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Figure 23: Mevalonate-isoprenoid biosynthesis pathway, its intermediates, and involved 
enzymes (Sharon et al., 2015). 
This figure shows the mevalonate-isoprenoid biosynthesis pathway. The pathway has an 
end product of Farnesyl pyrophosphate. Farnesyl pyrophosphate is responsible for the 
functioning of numerous cell processes including the electron transport chain. A crucial 
enzyme in this process, IDI-1, is also downregulated when IGF-1R is directly inhibited, 
indicating another mechanism of IGF-1R induced cell proliferation. 
 
Targeting the suppression of the PI3K/Akt/Wnt pathway in cancer stem cells using 
chemotherapeutic drugs causes many side effects and is not always necessary as the 
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damage from the drug might exceed the improvement in one’s lifestyle. Recent studies 
have examined the effects of dietary bioactive compounds in suppressing the IGF axis, 
and hence the PI3K/Akt pathways, in cancer stem cells. The discovered bioactive 
compounds in one review and their proposed mechanisms of action are shown in their 
figure below (Kasdagly et al., 2014). 
 
Figure 24: Proposed mechanism of action of bioactive compounds in preventing cellular 
proliferation (Kasdagly et al., 2014). 
As shown in this figure, Resveratrol (found in berries), Lycopene (found in tomatoes), 
and Curcumin use components of the PI3K/AKT/Wnt pathway to prevent proliferation. 
This pathway is essential in IGF-1 mediated cellular proliferation in CRC as discussed 
above. 
 
Of the mentioned compounds above, curcumin is a widely studied one. Curcumin 
suppresses the IGF axis by inhibiting proprotein convertases, specifically the ones 
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responsible for cleaving pro-IGF-1R into IGF-1R ( Zhu et al., 2013). In addition 
curcumin has also been shown to decrease the secretion of IGF-1 and increase the levels 
of IGFBP3 (Shehzad et al., 2012). 
Another study noted the role of t10, c12-CLA, which is found in small amounts in 
synthetic CLA and dairy products. t10, c12-CLA suppressed proliferation in a CRC cell 
line by inhibiting the phosphorylation of Akt (Kim et al., 2015). 
The role of these compounds would be especially important in the prevention of CRC. 
But the levels at which these compounds must be consumed in order to prevent CRC are 
up to speculation as most of the current studies have been performed in vitro and cannot 
yet be translated to a clinical setting. The figure below summarizes most of the bioactive 
compounds and where they could be found in one’s diet. 
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Figure 25: Bioactive dietary compounds known to interfere with IGF signaling pathway 
(Brahmkhatri et al., 2015). 
This figure illustrates the numerous compounds in our diet which potentially have a role 
in preventing CRC through their inhibition of the IGF axis. Turmeric powder, tomatoes, 
watermelon, berries, green tea, and grape are just some of the examples indicating the 
need for a more plant based diet in CRC prevention. 
 
Finally, a major component of one’s diet which can prevent CRC through the IGF 
pathway is Vitamin D. It was initially discovered that high levels of vitamin D are 
effective at reducing the incidence of CRC but the mechanism was unclear (Potter & 
Hunter, 2009). Recent evidence, however, has suggested that higher levels of vitamin D 
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are especially effective at reducing CRC induced due to high levels of IGF-1 and insulin 
(Tsai & Giovannucci, 2012). Furthermore, vitamin D has also shown to be able to 
effective at preventing CRC when levels of IGFBP3 have been low in comparison to 
IGF-1. It has been suggest that it performs this role by binding to the IGFBP3-vitamin D 
response element on the IGFBP3 promoter and hence increases the transcription of 
IGFBP3 (Wu et al., 2011). But further studies are still needed to determine the dosing 
regimen required to potentially use vitamin D as a treatment for CRC. 
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5. CONCLUSION 
 
The IGF axis’ dysregulation is of great importance in the biology and treatment of CRC.  
It has the ability to be influenced by numerous endogenous as well as exogenous 
compounds. This can have negative repercussions as it may be difficult to prevent the 
dysregulation of the IGF-1 pathway. However, it also provides a wide range of treatment 
options when treating patients with CRC. Depending on the needs of the patient, they 
could be provided with a treatment which is specific to IGF axis’ upregulation on cellular 
proliferation, like liposomes with miRNAs. Broad spectrum chemotherapeutic drugs may 
also be administered to the patient. Although these drugs will impact many other, 
unnecessary, pathways, their effect will be immediate and pronounced. Lastly, they could 
also be provided a less potent option, including bioactive compounds, which would have 
fewer side effects and have a role in preventative medicine. 
The mechanism through which the IGF axis may be causing CRC is becoming more 
known with respect to its role in cellular proliferation. However, the metastatic potential 
of this axis is still largely unclear and lacks fundamental mechanistic pathways. Further 
studies are required to enhance one’s knowledge on this matter. 
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